
Evoke Pharma Inc
NASDAQ:EVOK

Intrinsic Value
The intrinsic value of one
EVOK
stock under the Base Case scenario is
80.3
USD.
Compared to the current market price of 3.09 USD,
Evoke Pharma Inc
is
Undervalued by 96%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Fundamental Analysis


Revenue & Expenses Breakdown
Evoke Pharma Inc
Balance Sheet Decomposition
Evoke Pharma Inc
Current Assets | 17.2m |
Cash & Short-Term Investments | 13.6m |
Receivables | 2.4m |
Other Current Assets | 1.2m |
Non-Current Assets | 281.1k |
PP&E | 154.2k |
Other Non-Current Assets | 126.9k |
Free Cash Flow Analysis
Evoke Pharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Evoke Pharma Inc
Revenue
|
10.2m
USD
|
Cost of Revenue
|
-356.5k
USD
|
Gross Profit
|
9.9m
USD
|
Operating Expenses
|
-15.1m
USD
|
Operating Income
|
-5.2m
USD
|
Other Expenses
|
-148.1k
USD
|
Net Income
|
-5.4m
USD
|
EVOK Profitability Score
Profitability Due Diligence
Evoke Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Score
Evoke Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
EVOK Solvency Score
Solvency Due Diligence
Evoke Pharma Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Score
Evoke Pharma Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVOK Price Targets Summary
Evoke Pharma Inc
According to Wall Street analysts, the average 1-year price target for
EVOK
is 18.36 USD
with a low forecast of 18.18 USD and a high forecast of 18.9 USD.
Dividends
Current shareholder yield for EVOK is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?